Featured Publications
Expression of CD30 as a biomarker to predict response to brentuximab vedotin
Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology 2016, 69: 155-158. PMID: 26648051, PMCID: PMC7064871, DOI: 10.1111/his.12914.Peer-Reviewed Original Research
2022
Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus.
Gru AA, Lim MS, Dogan A, Horwitz SM, Delabie J, Fu K, Peker D, Reddy VVB, Xu ML, Vij K, Slack GW, Miranda RN, Jagadeesh D, Lisano JM, Hsi ED, Torlakovic E. Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. Archives Of Pathology & Laboratory Medicine 2022, 147: 79-86. PMID: 35472771, DOI: 10.5858/arpa.2021-0270-oa.Peer-Reviewed Original ResearchMeSH KeywordsConsensusHodgkin DiseaseHumansImmunohistochemistryKi-1 AntigenLymphoma, T-Cell, PeripheralConceptsCD30 expressionPeripheral T-cell lymphomaClassic Hodgkin lymphomaT-cell lymphomaDifferential diagnostic considerationsHematologists/oncologistsExpert panel consensusCD30 positivityHodgkin's lymphomaPredictive biomarkersDiagnostic workupImmunohistochemistry testingLymphoma biopsiesTherapeutic decisionsDiagnostic considerationsCD30 immunohistochemistryConsensus recommendationsPanel consensusLymphomaPositive expressionBest practice recommendationsImmunohistochemistryTumor cellsPractice recommendationsPanel recommendationsIRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas
McQuaid DC, Katz SG, Xu ML. IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas. American Journal Of Clinical Pathology 2022, 158: 173-176. PMID: 35460405, PMCID: PMC10664184, DOI: 10.1093/ajcp/aqac044.Peer-Reviewed Original Research
2019
Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis
Xu ML, Gabali A, Hsi ED, Fedoriw Y, Vij K, Salama ME, Ramchandren R, O’Malley D, Wick MR, Battistella M, Gru AA. Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. The American Journal Of Surgical Pathology 2019, 44: e1-e14. PMID: 31567279, DOI: 10.1097/pas.0000000000001368.Peer-Reviewed Original Research